Cargando…
Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study
The spread of COVID-19 is accelerating. At present, there is no specific antiviral drugs for COVID-19 outbreak. This is a multicenter retrospective cohort study of patients with laboratory-confirmed COVID-19 infection pneumonia from 3 hospitals in Hubei and Guangdong province, 141 adults (aged ≥18 y...
Autores principales: | Xu, Ping, Huang, Jianping, Fan, Zhao, Huang, Wendi, Qi, Minghua, Lin, Xuwen, Song, Weidong, Yi, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Masson SAS on behalf of Institut Pasteur.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238991/ https://www.ncbi.nlm.nih.gov/pubmed/32445881 http://dx.doi.org/10.1016/j.micinf.2020.05.012 |
Ejemplares similares
-
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
por: Deng, Lisi, et al.
Publicado: (2020) -
Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study
por: Zhou, Xianlong, et al.
Publicado: (2021) -
Beneficial effect of Arbidol in the management of COVID-19 infection
por: Jie, Xiong, et al.
Publicado: (2021) -
Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19
por: Liu, Lei, et al.
Publicado: (2021) -
Efficacy of arbidol in COVID-19 patients: A retrospective study
por: Wei, Shuo, et al.
Publicado: (2021)